home / stock / fbio / fbio news

FBIO News and Press, Fortress Biotech Inc. From 11/10/23

Stock Information
Company Name: Fortress Biotech Inc.
Stock Symbol: FBIO
Market: NASDAQ
Website: fortressbiotech.com
Menu
FBIO FBIO Quote FBIO Short FBIO News FBIO Articles FBIO Message Board
Get FBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
FBIO - Fortress Biotech Announces Pricing of $10.0 Million Public Offering

MIAMI, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product c...
FBIO - Fortress Biotech announces launch of proposed public offering

2023-11-09 17:18:48 ET More on Fortress Biotech Fortress Biotech CEO acquires 100,000 company shares Journey Medical announces exclusive license agreement with Maruho Seeking Alpha’s Quant Rating on Fortress Biotech For further details see: Fortres...

FBIO - Fortress Biotech Announces Launch of Proposed Public Offering

MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product c...

FBIO - Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share bas...
FBIO - Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the...

FBIO - Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

WORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and...

FBIO - Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the...
FBIO - Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

SCOTTSDALE, Ariz., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical product...

FBIO - Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for...

FBIO - Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for...
Previous 10 Next 10